The aqueous suspension technology for procaine benzylpenicillin represents the largest-volume veterinary dosage form derived from the procaine API platform. Particle size distribution exerts a controlling influence on both pharmacokinetic release profile and syringeability through intramuscular needles. Median particle diameter for sustained-release veterinary injectables typically falls between 8 μm and 25 μm, with a D₉₀ not exceeding 45 μm to prevent needle occlusion during administration through 18G to 20G hypodermic needles. The suspension vehicle incorporates sodium carboxymethylcellulose at 0.5–1.5% w/v as a viscosity-building agent to retard sedimentation velocity according to Stokes' law. Wetting of the hydrophobic procaine penicillin crystals is achieved with polysorbate 80 at 0.1–0.3% w/v or soybean lecithin at 0.1–0.2% w/v, incorporated via high-shear dispersion prior to final colloid milling. Homogenization is conducted through a toothed colloid mill with rotor-stator clearance set to 0.1–0.3 mm, followed by a high-pressure homogenizer operating at 300–600 bar for two to three passes. Terminal particle size verification employs laser diffraction analysis per USP <429>. Buffering of the aqueous phase to pH 5.5–6.5 with citric acid/sodium citrate maintains procaine penicillin stability; hydrolysis of the beta-lactam ring accelerates below pH 5.0 and above pH 7.5. Multi-dose vials require antimicrobial preservation—methylparaben at 0.1% w/v combined with propylparaben at 0.01% w/v meets the preservative efficacy requirements of USP <51>. Terminal sterilization cannot employ autoclaving due to thermal degradation of procaine penicillin above 60°C; gamma irradiation at 25 kGy provides a sterility assurance level of 10⁻⁶ but may generate free radicals that degrade the beta-lactam ring unless the formulation includes a radical scavenger. Aseptic filling through membrane filtration at 0.22 μm remains the preferred strategy for heat-sensitive procaine penicillin suspensions. Batch release testing includes USP <788> for particulate matter, USP <85> for bacterial endotoxins with a limit of 0.25 EU/mg, USP <71> for sterility, and VICH GL1 for analytical procedure validation. Production-scale failure modes documented on manufacturing lines include crystal bridging in the colloid mill feed hopper, caking of sediment in storage tanks exceeding 72 h hold time, and particle size drift when homogenization pressure deviates by more than ±50 bar from specified parameters.

What Limits Sterility Assurance Level in Aseptic Filtration of Procaine Hydrochloride Injection?

The formulation of procaine hydrochloride as a sterile local anesthetic injection for veterinary minor surgical procedures imposes stringent requirements on pH control and antioxidant selection. Procaine hydrochloride exhibits aqueous solubility of approximately 1 g/mL at 25°C, permitting simple dissolution in Water for Injection without co-solvents. Typical clinical concentrations range from 1.0% w/v to 2.0% w/v, with 4.0% w/v reserved for mucosal surface anesthesia in equine and bovine procedures. The pH of the finished solution must be adjusted to 3.0–5.5 using dilute hydrochloric acid or sodium hydroxide; below pH 3.0, tissue irritation upon injection escalates, while above pH 5.5, the ester linkage undergoes alkaline hydrolysis with liberation of p-aminobenzoic acid and diethylaminoethanol. Oxidation of procaine hydrochloride in solution proceeds via free-radical chain mechanisms catalyzed by dissolved oxygen and trace metal ions. Sodium metabisulfite at 0.1% w/v functions as the antioxidant of choice, although its sulfite content triggers hypersensitivity reactions in certain species—notably dogs. Alternative stabilization with 0.02% w/v disodium edetate chelates catalytic metal ions without sulfite-related adverse effects. Multi-dose formulations incorporate benzyl alcohol at 0.9% w/v as an antimicrobial preservative, but benzyl alcohol is contraindicated in feline injections due to documented toxicity at cumulative doses exceeding 45 mg/kg. Sterilization by steam autoclaving at 121°C for 15 min causes partial hydrolysis of procaine hydrochloride, generating p-aminobenzoic acid levels up to 0.5% after a single terminal cycle. Aseptic filtration through a 0.22 μm polyvinylidene fluoride membrane followed by filling into pre-sterilized Type I glass ampoules or vials avoids thermal degradation entirely. The filtration rate through a 0.22 μm membrane using a 10 cm cartridge at a differential pressure of 0.8 bar typically yields flux values of 200–400 L/m²/h for 2.0% w/v procaine hydrochloride at 20–25°C. Sterile filtration validation requires bubble point testing per ISO 2942 and bacterial challenge studies with Brevundimonas diminuta at a concentration of 10⁷ CFU/cm² membrane area. Terminal product testing for the local anesthetic injection includes USP <788> particulate matter, USP <1> injections general requirements, and assay by high-performance liquid chromatography with a specification of 95.0–105.0% of labeled claim. Onset of anesthetic action occurs within 2–5 min of infiltration injection, with duration limited to 30–60 min in the absence of a vasoconstrictor; addition of epinephrine at 1:100,000 extends duration to 90–120 min but introduces cardiovascular monitoring obligations.

Granulation Endpoint Control and Excipient Compatibility for Procaine Hydrochloride Tablets

The manufacture of procaine hydrochloride tablets for oral veterinary administration requires careful matching of granulation technology to API solubility and particle characteristics. Procaine hydrochloride crystals exhibit a plate-like morphology with a bulk density of 0.45–0.60 g/cm³, creating flow challenges during direct compression. Direct compression with microcrystalline cellulose at 30–50% w/w and spray-dried lactose monohydrate at 20–40% w/w is feasible for tablet strengths below 50 mg where API content remains under 15% w/w. Above this threshold, wet granulation in a high-shear mixer with a chopper speed of 1,500 rpm and impeller speed of 200–300 rpm is required to achieve acceptable content uniformity. Granulation liquid comprising purified water or 5% w/v povidone K30 solution is sprayed at a rate of 50–100 mL/min until the target endpoint moisture of 12–15% w/w is reached. Endpoint detection relies on impeller torque measurement; torque values rising to 1.5–2.0 N·m above the dry blend baseline indicate adequate granule formation. Wet mass is dried in a fluid bed dryer at an inlet air temperature of 60°C until loss on drying falls below 2.0% w/w. Dried granules are sized through a 1.0 mm stainless steel screen and blended with croscarmellose sodium at 2–4% w/w as a disintegrant and magnesium stearate at 0.5–1.0% w/w as a lubricant. Tableting on a rotary press with 16 stations operating at 40,000–60,000 tablets/h requires compression forces of 6–12 kN to achieve tablet hardness of 50–80 N. Dissolution testing per USP <711> Apparatus 2 (paddle) at 50 rpm in 900 mL of 0.1 N hydrochloric acid serves as the release-quality gate; specifications typically require Q ≥ 80% within 30 min. Film coating with hypromellose at 3–4% w/w weight gain is applied in a perforated pan coater with inlet air temperature of 70–80°C. The coated tablets are intended for oral administration to companion animals—predominantly dogs—for conditions including esophageal spasm and gastritis, with typical doses of 2–4 mg/kg body weight every 6–8 h. Stability studies conducted per VICH GL3 at 25°C/60% RH and 40°C/75% RH demonstrate assay retention above 95% for 24 months when the bulk API is stored below 25°C and protected from moisture.Feed premix production using procaine benzylpenicillin concentrates represents a distinct processing discipline where API particle size, carrier selection, and mixing geometry determine the homogeneity of final medicated feed. The active ingredient is received as a spray-dried or solvent-precipitated powder with a median particle size of 10–30 μm and a bulk density of 0.35–0.55 g/cm³. Carriers for veterinary premix products include calcium carbonate with a tapped density of 1.2–1.4 g/cm³, ground rice husk, and wheat middlings. The density differential between API and carrier creates segregation risk during pneumatic conveying and silo discharge. Ribbon blenders with a working volume of 500–2,000 L operating at 20–30 rpm for 15–20 min achieve mixture homogeneity characterized by a coefficient of variation below 5% for procaine penicillin content when measured on 10 stratified samples per batch. The premix is formulated at 10–15% w/w procaine benzylpenicillin activity, corresponding to 100,000–150,000 IU/g. Final feed incorporation dilutes this to 200–400 ppm active in complete feed for swine and poultry, equating to 200–400 IU/g feed. Loss on drying of the premix must remain below 1.0% w/w to prevent hydrolytic degradation during storage; heating the premix above 50°C during any processing step accelerates beta-lactam hydrolysis and reduces potency below specification within 60 days. Segregation testing per European Medicines Agency guidance for veterinary premixes requires sampling at 10 discharge points during silo emptying; acceptance criteria demand a relative standard deviation below 7% between samples. Dust control during premix manufacture requires local exhaust ventilation capturing particles below 10 μm; occupational exposure limits for penicillin-containing dust are set at 0.1 mg/m³ for the eight-hour time-weighted average in multiple jurisdictions, driven by severe hypersensitivity reactions in sensitized personnel. Batch-to-batch variance in procaine benzylpenicillin premix manufacturing typically originates from API particle size drift in the upstream spray-drying process; a shift of ±5 μm in median diameter alters bulk density by approximately 8–12% and directly impacts blend homogeneity and discharge flow rate from ribbon blenders.

Capsule Filling of Procaine-Containing Granulates Requires Tight Control of Carr Index

Encapsulation of procaine hydrochloride or procaine benzylpenicillin into hard gelatin capsules for veterinary oral administration is a low-complexity processing route constrained primarily by powder flow metrics. The powder blend must achieve a Carr index below 20% and a Hausner ratio below 1.25 for consistent fill weight on automatic capsule filling equipment. Procaine hydrochloride API with a Carr index of 28–33% in its native state requires dry granulation via roller compaction to improve flow. Roller compaction at a roll pressure of 60–100 MPa, roll speed of 5–10 rpm, and gap width of 2–4 mm yields ribbons that are milled through a 0.8 mm screen to produce granules with a Carr index of 12–16%. The granulated material is blended with microcrystalline cellulose at 15–20% and sodium starch glycolate at 2–3% to promote disintegration. Capsule filling on a 100,000 capsules/h machine requires fill weight control of ±5% of target; the dosing disk selection depends on granule bulk density and target fill. Dissolution testing for capsules per USP <711> is performed in 900 mL of simulated gastric fluid without enzymes at 37°C and 50 rpm paddle speed. Capsule shell selection (bovine gelatin vs. hydroxypropyl methylcellulose) affects disintegration time; gelatin capsules disintegrate within 15 min in aqueous media at 37°C, while HPMC capsules may require up to 30 min and exhibit temperature-dependent dissolution behavior. The terminal product is distributed to veterinary clinics and feedlot operations for oral administration to cattle and swine when individual animal dosing is required.Procaine hydrochloride is also formulated as a dry oral powder for reconstitution into a suspension at the point of use in veterinary practice. The powder blend comprises the API at 5–10% w/w, sucrose or sorbitol at 70–80% w/w as a sweetening and bulking agent, xanthan gum at 1–2% w/w as a suspending agent, and a flavoring component at 0.5–1.0% w/w. Sachet filling requires powder flow through volumetric cup fillers; the blend must achieve a Carr index below 15% to maintain fill weight variability within ±3% of label claim. Moisture content in the dry powder is controlled to below 1.0% w/w because procaine hydrochloride is hygroscopic above 60% RH, and moisture ingress accelerates hydrolysis of the ester bond. The dry powder is packaged in aluminum foil laminate sachets with moisture vapor transmission rates below 0.1 g/m²/24 h. Reconstitution with potable water to a final volume of 100 mL produces a suspension with a procaine hydrochloride concentration of 10 mg/mL. The reconstituted suspension is stable for 7 days at refrigerated temperature (2–8°C) and for 24 h at room temperature. Microbiological challenge testing of the reconstituted suspension per USP <51> demonstrates that preservative-free formulations support bacterial proliferation exceeding 10³ CFU/mL within 48 h, mandating either single-use packaging or addition of potassium sorbate at 0.1% w/v.

When Procaine Hydrochloride Dissolves in Aqueous Vehicles Without Antioxidant Protection

The preparation of procaine hydrochloride oral solutions for veterinary administration requires rigorous control of dissolved oxygen, pH, and light exposure to prevent degradation during shelf storage. Procaine hydrochloride in aqueous solution at 10 mg/mL to 50 mg/mL undergoes pH-dependent hydrolysis with a rate minimum between pH 3.5 and 4.5. Buffering with citric acid/sodium citrate at 0.05 M maintains this pH range, although buffering capacity is consumed slowly as procaine hydrolysis liberates diethylaminoethanol with a pK_a of 9.1. Dissolved oxygen accelerates oxidative degradation; nitrogen sparging of the vehicle at 0.5–1.0 L/min for 30 min per batch reduces dissolved oxygen to below 0.5 mg/L. Preservation of multi-dose oral solutions requires methylparaben at 0.1% w/v and propylparaben at 0.02% w/v, with preservative assay monitoring throughout the shelf life because paraben esters partition into plastic bottle materials and undergo gradual hydrolysis at a rate of 0.3–0.5% per month at 25°C. Packaging in amber polyethylene terephthalate bottles with a wall thickness of 1.5 mm reduces light transmission below 10% in the 290–450 nm range, the region where photolytic cleavage of the procaine ester bond is most pronounced. Storage at 25°C/60% RH per VICH GL3 demonstrates assay retention above 95% for 24 months when the pH is maintained at 4.0 ± 0.3 and the bottle remains sealed to exclude atmospheric oxygen. Once the oral solution is opened, a use period of 30 days at ambient temperature is supported by preservative efficacy data. Equipment considerations for oral solution manufacturing include stainless steel mixing vessels with polished surfaces (Ra ≤ 0.4 μm) to minimize drug adsorption and facilitate cleaning validation. The terminal product is administered via dosing syringe or added to drinking water for swine and poultry; in drinking water systems, procaine hydrochloride solutions must be protected from light and replenished every 24 h because the drug degrades by 15–20% in illuminated, aerated water over 24 h at 25°C.